Abbott Willfully Infringed On Innogenetics’ Hepatitis C Patent, Jury Finds
This article was originally published in The Gray Sheet
Executive Summary
Innogenetics is seeking an injunction against Abbott's hepatitis C genotyping reagents after a $7 mil. jury verdict in its favor